PEP8-TAT2, a membrane-permeable peptide, inhibits cyclin-Cdk2 activity in HeLa cells

Cancer Letters

Volumn 213, Issue 2, 2004, Pages 223-230

  Chun, Kwang Hoon ^a   Kim, Dae Kwon ^a   Nam, Yun Won ^a   Lee, Seung Ki ^a  

^a Seoul National University   (South Korea)

Author keywords

Apoptosis; Cdk, cyclin dependent protein kinase; Cell cycle; FBS, fetal bovine serum; HeLa cells; HIV, human immuno deficiency virus; PEP8 Cdk2 inhibitor peptide; PEP8 TAT2 transmembrane peptide; PTD, protein transduction domain

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; MW 3850; PACLITAXEL; PEPTIDE DERIVATIVE; TRANSACTIVATOR PROTEIN; TYROSYLSERYLPHENYLALANYLVALYLHISTIDYLHISTIDYLGLYCYLPHENYLALANYL PHENYLALANYLASPARAGINYLPHENYLALANYLARGINYLVALYLSERYLTRYPTOPHYLARGINYLGLUTAMYL METHIONYLLEUCYLALANYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYL ARGININE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; IC 50; MEMBRANE PERMEABILITY; PRIORITY JOURNAL;

AMINO ACID TRANSPORT SYSTEMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL ASSAY; CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CELL MEMBRANE; CYCLIN-DEPENDENT KINASE 2; DNA; HELA CELLS; HUMANS; PACLITAXEL; PEPTIDE FRAGMENTS; PERMEABILITY; SACCHAROMYCES CEREVISIAE PROTEINS;

BOVINAE;

EID: 4344712156     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.03.034     Document Type: Article

References (36)

1. Yam C.H., Fung T.K., Poon R.Y. Cyclin A in cell cycle control and cancer. Cell. Mol. Life Sci. 59:2002;1317-1326
2. Obaya A.J., Sedivy J.M. Regulation of cyclin-Cdk activity in mammalian cells. Cell. Mol. Life Sci. 59:2002;126-142
3. Stead E., White J., Faast R., Conn S., Goldstone S., Rathjen J., et al. Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. Oncogene. 21:2002;8320-8333
4. Sandal T., Stapnes C., Kleivdal H., Hedin L., Doskeland S.O. A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells. J. Biol. Chem. 277:2002;20783-20793
5. Katchanov J., Harms C., Gertz K., Hauck L., Waeber C., Hirt L., et al. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J. Neurosci. 21:2001;5045-5053
6. Morris E.J., Keramaris E., Rideout H.J., Slack R.S., Dyson N.J., Stefanis L., Park D.S. Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage. J. Neurosci. 21:2001;5017-5026
7. Chadebech P., Truchet I., Brichese L., Valette A. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int. J. Cancer. 87:2000;779-786
8. WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J. Biol. Chem. 275:2000;30256-30263
9. Tepper C.G., Seldin M.F., Mudryj M. Fas-mediated apoptosis of proliferating, transiently growth-arrested, and senescent normal human fibroblasts. Exp. Cell Res. 260:2000;9-19
10. Zhou B.B., Li H., Yuan J., Kirschner M.W. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc. Natl Acad. Sci. USA. 95:1998;6785-6790
11. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276:2001;251-260
12. Osuga H., Osuga S., Wang F., Fetni R., Hogan M.J., Slack R.S., et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc. Natl Acad. Sci. USA. 97:2000;10254-10259
13. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:2002;417-425
14. Gray N., Detivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6:1999;859-875
15. Davis S.T., Benson B.G., Bramson H.N., Chapman D.E., Dickerson S.H., Dold K.M., et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science. 291:2001;134-137
16. Schang L.M., Rosenberg A., Schaffer P.A. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 74:2000;2107-2120
17. Wang D., de la Fuente C., Deng L., Wang L., Zilberman I., Eadie C., et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75:2001;7266-7279
18. Doerig C., Meijer L., Mottram J.C. Protein kinases as drug targets in parasitic protozoa. Trends Parasitol. 18:2002;366-371
19. Rank K.B., Evans D.B., Sharma S.K. The N-terminal domains of cyclin-dependent kinase inhibitory proteins block the phosphorylation of cdk2/Cyclin E by the CDK-activating kinase. Biochem. Biophys. Res. Commun. 271:2000;469-473
20. WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 57:1997;1442-1446
21. WAF1. Curr. Biol. 7:1997;71-80
22. Fujimoto K., Hosotani R., Miyamoto Y., Doi R., Koshiba T., Otaka A., et al. Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells. Cancer Lett. 159:2000;151-158
23. Waf1/Cip1 carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 59:1999;3480-3488
24. Fahraeus R., Paramio J.M., Ball K.L., Lain S., Lane D.P. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol. 6:1996;84-91
25. Cohen B.A., Colas P., Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 380:1996;548-550
26. Cohen B.A., Colas P., Brent R. An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Natl Acad. Sci. USA. 95:1998;14272-14277
27. Wadia J.S., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 13:2002;52-56
28. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:1997;16010-16017
29. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1999;1569-1572
30. Vocero-Akbani A.M., Heyden N.V., Lissy N.A., Ratner L., Dowdy S.F. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 5:1999;29-33
31. Kip1 induces cell migration. Nat. Med. 4:1998;1449-1452
32. Lee K.Y., Park J.H., Chung M.H., Park Y.I., Kim K.W., Lee Y.J., Lee S.K. Aloesin up-regulates cyclin E/CDK2 kinase activity via inducing the protein levels of cyclin E, CDK2, and CDC25A in SK-HEP-1 cells. Biochem. Mol. Biol. Int. 41:1997;285-292
33. Abraham R.T., Acquarone M., Andersen A., Asensi A., Belle R., Berger F., et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell. 83:1995;105-120
34. Yao S.L., McKenna K.A., Sharkis S.J., Bedi A. Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1 beta-converting enzyme-related proteases. Cancer Res. 56:1996;4551-4555
35. Finkielstein C.V., Chen L.G., Maller J.L. A role for G1/S cyclin-dependent protein kinases in the apoptotic response to ionizing radiation. J. Biol. Chem. 277:2002;38476-38485
36. Kim S.G., Kim S.N., Jong H.S., Kim N.K., Hong S.H., Kim S.J., Bang Y.J. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene. 20:2001;1254-1265